Showing 4801-4810 of 6036 results for "".
- Visus Unveils Additional Ophthalmic Drug Candidates for Corneal Wound Healing, Glaucoma and AMDhttps://modernod.com/news/visus-unveils-additional-ophthalmic-drug-candidates-for-corneal-wound-healing-glaucoma-and-amd/2480276/During its inaugural Capital Markets Day in New York City, Visus Therapeutics unveiled additional ophthalmic drug candidates with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD). Additionally, the company introduced a novel drug
- Outlook Therapeutics Presents Positive NORSE THREE Safety Data for Lytenava (bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-presents-positive-norse-three-safety-data-for-lytenava-bevacizumab-vikg-at-euretina/2479575/Outlook Therapeutics announced the presentation of safety data from the NORSE THREE trial evaluating ONS-5010/Lytenava (bevacizumab-vikg) at the EURETINA Virtual 2021 conference on September 12, 2021. The previously announced topline results from the open-label safety study demonstrated that
- AbbVie Makes Large Investment in Regenxbio's Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-eye-care-collaboration/2479577/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patient
- World Council of Optometry Launches Myopia Management Online Resourcehttps://modernod.com/news/world-council-of-optometry-launches-myopia-management-online-resource/2479506/Building upon their efforts to establish a standard of care for myopia management, the World Council of Optometry (WCO) and CooperVision have jointly developed an easy-to-use online resource that provides multilingual assets and approaches that will enable busy eye care professionals—regardless o
- NIH-Funded Robotic Cane With 3D Camera Can Accurately Guide User to Chosen Locationhttps://modernod.com/news/nih-funded-robotic-cane-with-3d-camera-can-accurately-guide-user-to-chosen-location/2479504/Equipped with a color 3D camera, an inertial measurement sensor, and its own on-board computer, a newly improved robotic cane could offer blind and visually impaired users a new way to navigate indoors. When paired with a building’s architectural drawing, the device can accurately guide a user to
- Apellis Reports Mixed Phase 3 Results for Geographic Atrophy Drug; Will Pursue FDA Approvalhttps://modernod.com/news/apellis-announces-topline-results-from-phase-3-derby-and-oaks-studies-in-geographic-atrophy/2479503/Apellis Pharmaceuticals reported topline results from the phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). B
- ProQR Announces Axiomer RNA Editing Licensing and Research Collaboration with Lillyhttps://modernod.com/news/proqr-announces-axiomer-rna-editing-licensing-and-research-collaboration-with-lilly/2479498/ProQR Therapeutics, the developer of RNA therapies for the treatment of genetic eye diseases, announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in
- TearClear Files IND Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solutionhttps://modernod.com/news/tearclear-files-ind-application-to-begin-its-clinical-trial-for-tc-002-latanoprost-ophthalmic-solution/2479495/TearClear has filed an investigational new drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution 0.005%. Approximately 30%-40% of patients who rely on preserved, chronic glaucoma therapies show signs of moderat
- Pixium Vision Expands Collaboration with Stanford University On Next Generation Prima System Implantshttps://modernod.com/news/pixium-vision-expands-collaboration-with-stanford-university-on-next-generation-prima-system-implants/2479492/Pixium Vision SA announced the expansion of a collaboration with academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration (AMD). “We are very excited to be extending our collaboration with
- Oxurion to Present Clinical and Preclinical Data at Upcoming Euretina 2021 Virtual Congresshttps://modernod.com/news/oxurion-to-present-clinical-and-preclinical-data-at-upcoming-euretina-2021-virtual-congress/2479493/Oxurion NV will be presenting preclinical and clinical data from its ongoing development programs, THR-149 and THR-687, as novel treatments for diabetic macular edema (DME) at the Euretina 2021 virtual congress. The upcoming annual meeting of the European Society of Retina Specialists is taking p